Patents by Inventor Protul Shrikant

Protul Shrikant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11266691
    Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: March 8, 2022
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Protul Shrikant
  • Patent number: 11141432
    Abstract: Provided herein are materials and methods for treating a cancer and/or an infection in a mammal. One or more mitochondrial protein uncoupling protein 2 (UCP2) inhibitors can be administered to a mammal to enhance an immune response produced against an antigen (e.g., a tumor associated antigen or a pathogen associated antigen) present within the mammal.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 12, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Protul Shrikant, Leena Chaudhuri
  • Publication number: 20200237826
    Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Applicant: Mayo Foundation for Medical Education and Research
    Inventor: Protul Shrikant
  • Patent number: 10624925
    Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: April 21, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Protul Shrikant
  • Publication number: 20190076475
    Abstract: Provided herein are materials and methods for treating a cancer and/or an infection in a mammal. One or more mitochondrial protein uncoupling protein 2 (UCP2) inhibitors can be administered to a mammal to enhance an immune response produced against an antigen (e.g., a tumor associated antigen or a pathogen associated antigen) present within the mammal.
    Type: Application
    Filed: March 2, 2017
    Publication date: March 14, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Protul SHRIKANT, Leena CHAUDHURI
  • Publication number: 20180228839
    Abstract: This document provides methods and materials for producing CD8+ T cells. For example, methods and materials for using low glucose levels (e.g., from about 0.3 mM to about 0.7 mM glucose) to culture cells to produce particular populations of T cells (e.g., CD8+ T cells such as tissue resident memory T cells) are provided.
    Type: Application
    Filed: July 13, 2016
    Publication date: August 16, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventor: Protul Shrikant
  • Publication number: 20100196311
    Abstract: Provided are compositions and methods for enhancing immune responses to an antigen. The compositions contain an isolated population of CD8+T cells and an inhibitor of mammalian target of rapamycin (mTOR). The method for obtaining an enhanced immune response to an antigen in an individual entails administering to the individual the antigen and an inhibitor of mammalian target of rapamycin (mTOR). CD8+T cells may also be used for adoptive cell transfer (ACT) therapy.
    Type: Application
    Filed: January 14, 2010
    Publication date: August 5, 2010
    Inventors: Hyung L. Kim, Protul Shrikant, YanPing Wang, Qingsheng Li, Rajesh Rao